Carl Dambkowski, serving as the Chief Medical Officer for Apogee Therapeutics, Inc. (NASDAQ:APGE), completed a transaction involving the sale of 26,400 shares of the company's common stock on June 22, 2026. The aggregate value of this divestment reached approximately $3,500,640. Each share was disposed of at a weighted average price of $132.60, with the individual transactions transacting within a narrow price band ranging from $132.550 to $132.645.
The timing of this sale draws attention as the equity was trading in close proximity to its 52-week peak of $133.16. This price level reflects a substantial 209% return over the preceding year. According to analysis provided by InvestingPro, the current valuation of the stock appears elevated relative to its calculated Fair Value. Following the execution of these sales, Mr. Dambkowski maintains a direct holding of 179,248 shares of Apogee Therapeutics common stock.
The transaction was structured in compliance with a Rule 10b5-1 trading plan. Mr. Dambkowski originally adopted this specific plan on September 22, 2025, establishing the framework for the automated execution of the sale.
Corporate developments at Apogee Therapeutics include a definitive agreement to be acquired by AbbVie. The acquisition terms specify a cash consideration of $135.11 per share, resulting in a total enterprise valuation of approximately $10.9 billion. This strategic move follows encouraging clinical milestones for Apogee's lead program, zumilokibart, which is currently progressing into Phase III trials.
Market analysts have adjusted their perspectives following the acquisition announcement. Mizuho downgraded Apogee's stock rating from Buy to Neutral and simultaneously raised its price target to $135. UBS also initiated a downgrade to Neutral, noting that the proposed acquisition price aligns with fair value given the current development stage of Apogee's assets.
Further corporate activity includes the execution of two agreements with Paragon Therapeutics focused on the discovery and development of antibodies targeting the interleukin 31 receptor. Apogee also conducted its 2026 Annual Meeting of Stockholders, where directors were elected and various proposals received approval. Additionally, RBC Capital raised its price target for Apogee to $97 while maintaining a Sector Perform rating. This adjustment followed a survey of dermatologists regarding the potential future application of Apogee's product in the treatment of atopic dermatitis.
Market data indicates Apogee Therapeutics closed at $132.65, reflecting a decline of $0.23 or 0.17%. After-hours trading showed the stock at $132.60, a slight decrease of $0.09 or 0.07%. The stock's performance over the past year demonstrates significant volatility and growth, aligning with the broader biopharmaceutical sector's sensitivity to clinical trial outcomes and strategic partnerships.